Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer disease

Shiyong Peng, Joanne Wuu, Elliott J. Mufson, Margaret Fahnestock

Research output: Contribution to journalArticle

182 Citations (Scopus)

Abstract

Nerve growth factor (NGF) is critical for the regulation, differentiation, and survival of basal forebrain cholinergic neurons that degenerate in the late stage of Alzheimer disease (AD). The precursor of NGF (proNGF) is the predominant form of NGF in brain and is increased in end stage AD. To determine whether this increase in proNGF is an early or late change during the progression of cognitive decline, we used Western blotting to measure the relative amounts of proNGF protein in the parietal cortex from subjects clinically classified with no cognitive impairment (NCI; n = 20), mild cognitive impairment (MCI; n = 20), or mild to moderate AD (n = 19). We found that proNGF increased during the prodromal stage of AD. The amount of proNGF protein was 1.4-fold greater in the MCI group as compared to NCI, and was 1.6-fold greater in mild-moderate AD as compared to NCI, similar to our previous findings of a 2-fold increase in end stage AD. There was a negative correlation between proNGF levels and Mini Mental Status Examination (MMSE) score, demonstrating that the accumulation of proNGF is correlated with loss of cognitive function. These findings demonstrate that proNGF levels increase during the preclinical stage of AD and may reflect an early biological marker for the onset of AD.

Original languageEnglish
Pages (from-to)641-649
Number of pages9
JournalJournal of Neuropathology and Experimental Neurology
Volume63
Issue number6
StatePublished - Jun 1 2004
Externally publishedYes

Fingerprint

Nerve Growth Factor
Alzheimer Disease
Protein Precursors
Cognitive Dysfunction
Prodromal Symptoms
Parietal Lobe
Cholinergic Neurons
Cognition
Biomarkers
Western Blotting
Brain

Keywords

  • Alzheimer disease
  • Cholinergic
  • Nerve growth factor (NGF)
  • Neurodegeneration
  • Neurotrophic factor
  • Parietal cortex
  • Western blotting

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Neuroscience(all)

Cite this

Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer disease. / Peng, Shiyong; Wuu, Joanne; Mufson, Elliott J.; Fahnestock, Margaret.

In: Journal of Neuropathology and Experimental Neurology, Vol. 63, No. 6, 01.06.2004, p. 641-649.

Research output: Contribution to journalArticle

@article{8aeac47121e74d52b370be3c09d63cfe,
title = "Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer disease",
abstract = "Nerve growth factor (NGF) is critical for the regulation, differentiation, and survival of basal forebrain cholinergic neurons that degenerate in the late stage of Alzheimer disease (AD). The precursor of NGF (proNGF) is the predominant form of NGF in brain and is increased in end stage AD. To determine whether this increase in proNGF is an early or late change during the progression of cognitive decline, we used Western blotting to measure the relative amounts of proNGF protein in the parietal cortex from subjects clinically classified with no cognitive impairment (NCI; n = 20), mild cognitive impairment (MCI; n = 20), or mild to moderate AD (n = 19). We found that proNGF increased during the prodromal stage of AD. The amount of proNGF protein was 1.4-fold greater in the MCI group as compared to NCI, and was 1.6-fold greater in mild-moderate AD as compared to NCI, similar to our previous findings of a 2-fold increase in end stage AD. There was a negative correlation between proNGF levels and Mini Mental Status Examination (MMSE) score, demonstrating that the accumulation of proNGF is correlated with loss of cognitive function. These findings demonstrate that proNGF levels increase during the preclinical stage of AD and may reflect an early biological marker for the onset of AD.",
keywords = "Alzheimer disease, Cholinergic, Nerve growth factor (NGF), Neurodegeneration, Neurotrophic factor, Parietal cortex, Western blotting",
author = "Shiyong Peng and Joanne Wuu and Mufson, {Elliott J.} and Margaret Fahnestock",
year = "2004",
month = "6",
day = "1",
language = "English",
volume = "63",
pages = "641--649",
journal = "American Journal of Psychotherapy",
issn = "0002-9564",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer disease

AU - Peng, Shiyong

AU - Wuu, Joanne

AU - Mufson, Elliott J.

AU - Fahnestock, Margaret

PY - 2004/6/1

Y1 - 2004/6/1

N2 - Nerve growth factor (NGF) is critical for the regulation, differentiation, and survival of basal forebrain cholinergic neurons that degenerate in the late stage of Alzheimer disease (AD). The precursor of NGF (proNGF) is the predominant form of NGF in brain and is increased in end stage AD. To determine whether this increase in proNGF is an early or late change during the progression of cognitive decline, we used Western blotting to measure the relative amounts of proNGF protein in the parietal cortex from subjects clinically classified with no cognitive impairment (NCI; n = 20), mild cognitive impairment (MCI; n = 20), or mild to moderate AD (n = 19). We found that proNGF increased during the prodromal stage of AD. The amount of proNGF protein was 1.4-fold greater in the MCI group as compared to NCI, and was 1.6-fold greater in mild-moderate AD as compared to NCI, similar to our previous findings of a 2-fold increase in end stage AD. There was a negative correlation between proNGF levels and Mini Mental Status Examination (MMSE) score, demonstrating that the accumulation of proNGF is correlated with loss of cognitive function. These findings demonstrate that proNGF levels increase during the preclinical stage of AD and may reflect an early biological marker for the onset of AD.

AB - Nerve growth factor (NGF) is critical for the regulation, differentiation, and survival of basal forebrain cholinergic neurons that degenerate in the late stage of Alzheimer disease (AD). The precursor of NGF (proNGF) is the predominant form of NGF in brain and is increased in end stage AD. To determine whether this increase in proNGF is an early or late change during the progression of cognitive decline, we used Western blotting to measure the relative amounts of proNGF protein in the parietal cortex from subjects clinically classified with no cognitive impairment (NCI; n = 20), mild cognitive impairment (MCI; n = 20), or mild to moderate AD (n = 19). We found that proNGF increased during the prodromal stage of AD. The amount of proNGF protein was 1.4-fold greater in the MCI group as compared to NCI, and was 1.6-fold greater in mild-moderate AD as compared to NCI, similar to our previous findings of a 2-fold increase in end stage AD. There was a negative correlation between proNGF levels and Mini Mental Status Examination (MMSE) score, demonstrating that the accumulation of proNGF is correlated with loss of cognitive function. These findings demonstrate that proNGF levels increase during the preclinical stage of AD and may reflect an early biological marker for the onset of AD.

KW - Alzheimer disease

KW - Cholinergic

KW - Nerve growth factor (NGF)

KW - Neurodegeneration

KW - Neurotrophic factor

KW - Parietal cortex

KW - Western blotting

UR - http://www.scopus.com/inward/record.url?scp=2942536284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942536284&partnerID=8YFLogxK

M3 - Article

C2 - 15217092

AN - SCOPUS:2942536284

VL - 63

SP - 641

EP - 649

JO - American Journal of Psychotherapy

JF - American Journal of Psychotherapy

SN - 0002-9564

IS - 6

ER -